Long before COVID’s arrival, antibiotic-resistance was a quiet global pandemic. Now that secondary bacterial infections are killing so many vulnerable patients in the COVID era, the pressure is growing for policy makers to finally address the antibiotics market failure. A cardiologist-turned-biotech entrepreneur explains why the superbugs always win.
Podden och tillhörande omslagsbild på den här sidan tillhör Biotechnology Innovation Organization. Innehållet i podden är skapat av Biotechnology Innovation Organization och inte av, eller tillsammans med, Poddtoppen.
